Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC-MSCs for COVID-19 Pneumonia
NCT05286255Phase 1Withdrawn
- Sponsor
- Medical University of South Carolina
- Start
- Oct 2024
- Primary completion
- Oct 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of umbilical cord-derived mesenchymal stromal cells in COVID-19 pneumonia and viral pneumonia, sponsored by Medical University of South Carolina. Primary endpoint: Rapid deterioration of respiratory or clinical status at 6 hours. Planned start Oct 2024; status: withdrawn.
02
Drugs
umbilical cord-derived mesenchymal stromal cells
03
Conditions
COVID-19 pneumoniaviral pneumonia
Beyond the preview
Go deeper on NCT05286255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05286255.